Vagal nerve stimulation for drug-resistant epilepsy: Efficacy and adverse events in an epilepsy centre with long-term follow-up

Timárová, Gabriela; Rivera, G.A. Ramos; Kolníková, Miriam; Novotný, Miroslav; Šteňo, Andrej; Sýkora, P.; Štěňo, Juraj

doi:10.1016/j.jns.2017.08.1945

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Duration of epilepsy on the outcome of VNS between the responders and non-responders. responder rate, as well as short duration of epilepsy [14,27,[29][30][31], but Soleman et al thought age at implantation did not influence the responder rate [32], which agrees with our study. Those different results may be caused by the small samples of patients of those studies; thus, through systematically evaluating the literature, our study suggested that DRE patients with shorter duration of epilepsy may be better candidates for VNS and they are easier to help attain seizure reduction, rather than those who are younger at onset and implantation.…”

Section: Discussionsupporting

confidence: 90%

Predictors of seizure reduction outcome after vagus nerve stimulation in drug-resistant epilepsy

Wang

Tan

Zhu

et al. 2019

Seizure

View full text Add to dashboard Cite

A B S T R A C TPurpose: To evaluate the predictors of seizure reduction outcome after vagus nerve stimulation (VNS) in patients with drug-resistant epilepsy (DRE). Methods: A meta-analysis was performed using relevant research from databases such as PubMed, Embase, Cochrane Online Library, and Clinicaltrials.gov. Studies were selected according to predefined inclusion and exclusion criteria. The quality of studies was evaluated by using the Newcastle-Ottawa Scale (NOS) scale. All data was pooled by STATA 12.0 software for meta-analysis. Results: The review considered 1281 articles, and 16 articles with NOS score ≥6 were included in the analysis. The meta-analysis showed that at 6 m, 1, 2, 3, 4, 6 and 12 years after implantation, 33.99, 43.42, 46.50, 63.31, 52.71, 54.64, 70.37 and 82.90% of patients exhibited > 50% reduction of seizure frequency after VNS. The duration of epilepsy showed a significant difference between the good responders and poor responders (p = 0.038), whereas age at VNS implantation (p = 0.305), age at seizure onset (p = 0.530), seizure type (p = 0.11), etiology (p = 0.187), and history of previous epilepsy surgery (p = 0.075) were not predictors of seizure reduction outcome after VNS. Several features about the electroencephalogram (EEG) feature and heart rhythm complexity (HRV) have not been analyzed by a sufficient number of studies. Conclusions: DRE patients with shorter duration of epilepsy may be better candidates for VNS rather than those who are younger at onset and implantation. Several EEG or HRV features may have predictive value but more research is needed.

show abstract

Section: Discussionsupporting

confidence: 90%

Predictors of seizure reduction outcome after vagus nerve stimulation in drug-resistant epilepsy

Wang

Tan

Zhu

et al. 2019

Seizure

View full text Add to dashboard Cite

show abstract

The Role of Neurosurgery in Global Health Epilepsy, Movement Disorders, and Psychiatric Diseases

Kanmounye¹,

Angelov

Pannullo

et al. 2022

Neurosurgery and Global Health

View full text Add to dashboard Cite

The effectiveness of vagus nerve stimulation after failed surgical treatment of pharmacoresistant epilepsy

Трифонов

Синкин²,

Nekhoroshikh³

2021

Vestnik Nevrologii, Psihiatrii I Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)

View full text Add to dashboard Cite

According to the WHO, about 50 million people in the world suffer from epilepsy, while 20–40 % are resistant to antiepileptic drugs and need alternative treatment methods. The arsenal of neurosurgeons includes a wide range of operations that have proven effectiveness in the fight against pharmacoresistant epilepsy. Such a promising type of treatment as vagus nerve stimulation can be used both with contraindicated resection surgery and after it. Currently, the field of VNS therapy continues to be explored, including the efficiency and rationality of its use.

show abstract

Vagal nerve stimulation for drug-resistant epilepsy: Efficacy and adverse events in an epilepsy centre with long-term follow-up

Cited by 3 publications

References 0 publications

Predictors of seizure reduction outcome after vagus nerve stimulation in drug-resistant epilepsy

Predictors of seizure reduction outcome after vagus nerve stimulation in drug-resistant epilepsy

The Role of Neurosurgery in Global Health Epilepsy, Movement Disorders, and Psychiatric Diseases

The effectiveness of vagus nerve stimulation after failed surgical treatment of pharmacoresistant epilepsy

Contact Info

Product

Resources

About